Alpelisib (ALP) plus endocrine therapy (ET) by last prior therapy in patients (pts) with PIK3CA-mutated hormone-receptor positive (HR plus ) human epidermal growth factor receptor-2-Negative (HER2-) advanced breast cancer (ABC): Additional study cohort in BYLieve

被引：0
|
作者：
Ciruelos, E. [1 ]
Lerebours, F. [2 ]
Ruiz Borrego, M. [3 ]
Bachelot, T. [4 ]
Polikoff, J. [5 ]
Chia, S. [6 ]
Juric, D. [7 ]
Turner, N. [8 ,9 ]
Ridolfi, A. [10 ]
Sophos, N. [11 ]
Cooper, B. [12 ]
Thuerigen, A. [13 ]
Rugo, H. S. [14 ]
机构：
[1] Univ Hosp 12 Octubre, Med Oncol, Madrid, Spain
[2] Hop Rene Huguenin, Dept Oncol, Inst Curie, St Cloud, France
[3] Hosp Univ Virgen del Rocio, Dept Oncol, Seville, Spain
[4] Ctr Leon Berard, Dept Oncol, Lyon, France
[5] Kaiser Permanente Southern Calif, Dept Oncol, San Diego, CA USA
[6] Univ British Columbia, Dept Med, Vancouver, BC, Canada
[7] Massachusetts Gen Hosp, Dept Oncol, Boston, MA 02114 USA
[8] Inst Canc Res, Dept Oncol, London, England
[9] Royal Marsden Hosp, London, England
[10] Novartis Pharmaceut, Rueil Malmaison, France
[11] Novartis Pharmaceut, Global Oncol, E Hanover, NJ USA
[12] Novartis Pharmaceut, Oncol Med Affairs, E Hanover, NJ USA
[13] Novartis Pharmaceut, Oncol Med Affairs, Basel, Switzerland
[14] UCSF Helen Diller Family Comprehens Canc Ctr, Breast Canc Ctr, San Francisco, CA USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
388TiP
引用
收藏
页码：141 / 141
页数：1
相关论文
共 50 条
  • [11] THE ALPELISIB (ALP) EXPERIENCE IN THE SOLAR-1 AND BYLIEVE STUDIES: PERSPECTIVES FOR PRACTITIONERS CARING FOR PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC)
    Rugo, Hope S.
    Andre, Fabrice
    Park, Yeon Hee
    Drullinsky, Pamela
    Loibl, Sibylle
    Cardoso, Fatima
    Mason, Ginny
    Aubel, Dawn
    Lorenzo, Ines
    Akdere, Murat
    Ciruelos, Eva M.
    BREAST, 2021, 59 : S49 - S49
  • [12] Patient-reported outcomes (PROs) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2) advanced breast cancer (ABC) from SOLAR-1.
    Mayer, Ingrid A.
    Rugo, Hope S.
    Loibl, Sibylle
    Safra, Tamar
    Park, Yeon Hee
    Krivorotko, Petr
    Iwata, Hiroji
    Andre, Fabrice
    Conte, Pier Franco
    Ciruelos, Eva
    Juric, Dejan
    Park, Jinhee
    Wilke, Celine
    Mills, David
    Lteif, Agnes
    Campone, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [13] Antineoplastic (ANP) therapies (Tx) after alpelisib (ALP) or placebo (PBO) plus fulvestrant (FUL) in patients (Pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (Mut) advanced breast cancer (ABC): An analysis from SOLAR-1
    Andre, F.
    Rugo, H. S.
    Juric, D.
    Rubovsky, G.
    Yamashita, T.
    Stemmer, S. M.
    Lu, Y- S.
    Miller, M. K.
    Lorenzo, I.
    Hu, H.
    Ciruelos, E. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S498 - S499
  • [14] Impact of ESR1 mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial
    Turner, Nick
    Rugo, Hope S.
    Ciruelos, Eva M.
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Lerebours, Florence
    Prat, Aleix
    Bachelot, Thomas
    Chia, Stephen
    Balbin, Alejandro
    Joshi, Mukta
    Roux, Estelle
    Arce, Christina H.
    Akdere, Murat
    Juric, Dejan
    CANCER RESEARCH, 2022, 82 (04)
  • [15] Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with hormone receptorpositive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study.
    Dejan, Juric
    Rugo, Hope S.
    Chia, Stephen K. L.
    Lerebours, Florence
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Ciruelos, Eva M.
    Neven, Patrick
    Park, Yeon Hee
    Arce, Christina H.
    Gu, Ennan
    Joshi, Mukta
    Roux, Estelle
    Akdere, Murat
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [16] Alpelisib plus endocrine therapy (ET) in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study
    Juric, Dejan
    Turner, Nicholas
    Prat, Aleix
    Chia, Stephen
    Ciruelos, Eva M.
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Lerebours, Florence
    Bachelot, Thomas
    Balbin, O. Alejandro
    Joshi, Mukta
    Roux, Estelle
    Arce, Christina H.
    Akdere, Murat
    Rugo, Hope S.
    CANCER RESEARCH, 2022, 82 (04)
  • [17] CompLEEment-1: Phase 3b study of ribociclib plus letrozole for the treatment of hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in patients with no prior endocrine therapy (ET) for ABC
    De Laurentiis, M.
    Martin Jimenez, M.
    Ring, A.
    Cottu, P.
    Zhou, K.
    Wu, J.
    Zarate, J. P.
    Zamagni, C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [18] Ribociclib (RIBO) plus letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial
    Abdel-Razeq, H.
    Cottu, P. H.
    Ring, A.
    De laurentiis, M.
    Lu, J.
    Azim, H. A.
    Zamagni, C.
    Zhou, K.
    Wu, J.
    Menon, L.
    Martin, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [19] Expert consensus recommendations for managing hyperglycemia and rash in patients with PK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with alpelisib (ALP)
    Gallagher, Emily J.
    Moore, Heather
    Lacouture, Mario E.
    Dent, Susan Faye
    Farooki, Azeez
    Goncalves, Marcus D.
    Isaacs, Claudine
    Johnston, Abigail
    Juric, Dejan
    Quandt, Zoe
    Spring, Laura
    Berman, Brian
    Decker, Melanie
    Hortobagyi, Gabriel N.
    Kaffenberger, Benjamin
    Kwong, Bernice Y.
    Pluard, Timothy J.
    Rao, Ruta D.
    Schwartzberg, Lee S.
    Broder, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 422 - 422
  • [20] Ribociclib (RIBO) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial
    Zamagni, C.
    Campone, M.
    Kudryavcev, I.
    Brown-Glaberman, U.
    Cottu, P. H.
    Ring, A.
    Lu, J.
    Martin, M.
    De laurentiis, M.
    Zhou, K.
    Wu, J.
    Menon, L.
    Azim, H. A.
    ANNALS OF ONCOLOGY, 2018, 29
12345